Drug General Information
Drug ID	D0Z4FE
Former ID	DIB007601
Drug Name	MIN-117
Indication	Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]		Phase 2	[549451]
Company	Minerva neurosciences
Structure		Download 2D MOL
Target and Pathway
Target(s)	5-hydroxytryptamine 1A receptor	Target Info	Antagonist	[550002]
KEGG Pathway	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Serotonergic synapse
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	5HT1 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (i) signalling events
WikiPathways	Serotonin HTR1 Group and FOS Pathway
	SIDS Susceptibility Pathways
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 549451	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037483)
Ref 550002	Company report (Minerva Neurosciences),MIN-101,Schizophrenia, 6 trials completed; Once a day formulation completed , Phase IIa completed; Phase IIb enrollment ongoing and expected to continue over the last 3 quarters of 2015.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.